{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:03:26Z","timestamp":1769256206718,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004853","name":"The Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.lanwpc.2025.101696","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:14:01Z","timestamp":1759346041000},"page":"101696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Trends of lipid-lowering drug utilization, treatment intensity and LDL-C target attainment in adults with diabetes and non-dialysis chronic kidney disease in Hong Kong"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6297-5418","authenticated-orcid":false,"given":"Yanting","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiazhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-1114","authenticated-orcid":false,"given":"Hongjiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana N.M.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-6764","authenticated-orcid":false,"given":"Alice P.S.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald C.W.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea O.Y.","family":"Luk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana C.N.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-3387","authenticated-orcid":false,"given":"Elaine","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanwpc.2025.101696_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110924","article-title":"Association of eGFR slope with all-cause mortality, macrovascular and microvascular outcomes in people with type 2 diabetes and early-stage chronic kidney disease","volume":"205","author":"Jin","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"9607","key":"10.1016\/j.lanwpc.2025.101696_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101696_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010006","article-title":"Antidyslipidemia pharmacotherapy in chronic kidney disease: a systematic review and bayesian network meta-analysis","volume":"15","author":"Liao","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101696_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cpt.1859","article-title":"Effects and safety of statin and ezetimibe combination therapy in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"108","author":"Lin","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.lanwpc.2025.101696_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11883-019-0778-6","article-title":"Recent updates on the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease","volume":"21","author":"Dixon","year":"2019","journal-title":"Curr Atheroscler Rep"},{"issue":"23","key":"10.1016\/j.lanwpc.2025.101696_bib6","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"10.1016\/j.lanwpc.2025.101696_bib7","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.lanwpc.2025.101696_bib8","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lanwpc.2025.101696_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"issue":"25 Pt B","key":"10.1016\/j.lanwpc.2025.101696_bib10","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101696_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12933-020-01039-y","article-title":"Trends in diabetes-related complications in Hong Kong, 2001-2016: a retrospective cohort study","volume":"19","author":"Wu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101696_bib12","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/ije\/dyab252","article-title":"Data resource profile: the Hong Kong diabetes surveillance database (HKDSD)","volume":"51","author":"Wu","year":"2022","journal-title":"Int J Epidemiol"},{"issue":"9","key":"10.1016\/j.lanwpc.2025.101696_bib13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101696_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M18-0543","article-title":"ESPACOMP medication adherence reporting guideline (EMERGE)","volume":"169","author":"De Geest","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lanwpc.2025.101696_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102568","article-title":"Clinical outcomes following discontinuation of metformin in patients with type 2 diabetes and advanced chronic kidney disease in Hong Kong: a territory-wide, retrospective cohort and target trial emulation study","volume":"71","author":"Yang","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101696_bib16","first-page":"115","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"70","author":"Catapano","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"Supplement_1","key":"10.1016\/j.lanwpc.2025.101696_bib17","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.lanwpc.2025.101696_bib18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.7326\/M23-0442","article-title":"Achievement of guideline-recommended targets in diabetes care in China : a nationwide cross-sectional study","volume":"176","author":"Zhong","year":"2023","journal-title":"Ann Intern Med"},{"issue":"14","key":"10.1016\/j.lanwpc.2025.101696_bib19","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/eurjpc\/zwac103","article-title":"Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020","volume":"29","author":"Chobufo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.lanwpc.2025.101696_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S2213-8587(22)00072-9","article-title":"Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study","volume":"10","author":"Anjana","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.lanwpc.2025.101696_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1053\/j.ajkd.2024.11.003","article-title":"Use of statins for primary prevention among individuals with CKD in the United States: a cross-sectional, time-trend analysis","volume":"85","author":"Iyalomhe","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.lanwpc.2025.101696_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.18808","article-title":"Concordance with screening and treatment guidelines for chronic kidney disease in type 2 diabetes","volume":"7","author":"Edmonston","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.lanwpc.2025.101696_bib23","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.2337\/dci19-0003","article-title":"From Hong Kong diabetes register to JADE program to RAMP-DM for data-driven actions","volume":"42","author":"Chan","year":"2019","journal-title":"Diabetes Care"},{"issue":"2\u20133","key":"10.1016\/j.lanwpc.2025.101696_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.healthpol.2012.08.008","article-title":"Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour","volume":"108","author":"Wallach Kildemoes","year":"2012","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101696_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12944-023-01833-z","article-title":"International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?","volume":"22","author":"Calice-Silva","year":"2023","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101696_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacl.2019.01.009","article-title":"Comparative aspects of the care of familial hypercholesterolemia in the \u201cTen Countries Study\u201d","volume":"13","author":"Pang","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.lanwpc.2025.101696_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00228-021-03242-6","article-title":"Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies","volume":"78","author":"Bagepally","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101696_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: a meta-analysis","volume":"28","author":"Silva","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.lanwpc.2025.101696_bib31","series-title":"Evidence review for statins: efficacy and adverse effects: cardiovascular disease: risk assessment and reduction, including lipid modification: evidence review C","year":"2023"},{"issue":"5","key":"10.1016\/j.lanwpc.2025.101696_bib32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/clpt.2009.232","article-title":"ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin","volume":"87","author":"Tomlinson","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.lanwpc.2025.101696_bib33","article-title":"2023 Chinese guideline for lipid management","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.lanwpc.2025.101696_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/1755-5922.12214","article-title":"Safety of atorvastatin in Asian patients within clinical trials","volume":"34","author":"Chan","year":"2016","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"10.1016\/j.lanwpc.2025.101696_bib35","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11606-021-06651-6","article-title":"The risk of muscular events among new users of hydrophilic and lipophilic statins: an observational cohort study","volume":"36","author":"Mueller","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"11","key":"10.1016\/j.lanwpc.2025.101696_bib36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.lanwpc.2025.101696_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ahj.2024.06.012","article-title":"Achievement of LDL-C <55 mg\/dL among US adults: findings from the cvMOBIUS2 registry","volume":"279","author":"Navar","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.lanwpc.2025.101696_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2261-15-6","article-title":"The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report","volume":"15","author":"Li","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101696_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.12809\/hkmj165045","article-title":"2016 Consensus statement on prevention of atherosclerotic cardiovascular disease in the Hong Kong population","volume":"23","author":"Cheung","year":"2017","journal-title":"Hong Kong Med J"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101696_bib40","first-page":"90","article-title":"Call to action: bridging gaps in lipid management in Hong Kong","volume":"30","author":"Yan","year":"2024","journal-title":"Hong Kong Med J"},{"issue":"15","key":"10.1016\/j.lanwpc.2025.101696_bib41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/heartjnl-2023-323722","article-title":"Sex differences in the intensity of statin prescriptions at initiation in a primary care setting","volume":"110","author":"Kiss","year":"2024","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101696_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jep.12462","article-title":"Statin prescribing according to gender, age and indication: what about the benefit-risk balance?","volume":"22","author":"Wallach-Kildemoes","year":"2016","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.lanwpc.2025.101696_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100180","article-title":"Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues","volume":"6","author":"Langslet","year":"2021","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.lanwpc.2025.101696_bib44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00125-020-05319-w","article-title":"Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses","volume":"64","author":"Nanayakkara","year":"2021","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.lanwpc.2025.101696_bib45","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/dc20-0260","article-title":"Trends in glucose-lowering drug use, glycemic control, and severe hypoglycemia in adults with diabetes in Hong Kong, 2002\u20132016","volume":"43","author":"Yang","year":"2020","journal-title":"Diabetes Care"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606525002354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606525002354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:33:42Z","timestamp":1761950022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606525002354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"alternative-id":["S2666606525002354"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101696","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends of lipid-lowering drug utilization, treatment intensity and LDL-C target attainment in adults with diabetes and non-dialysis chronic kidney disease in Hong Kong","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101696"}}